Long-acting bronchodilator therapy should be considered when a COPD patient is symptomatic. For patients whose conditions are not sufficiently controlled by monotherapy, combining medications of different classes seems a convenient treatment for obtaining better results. The current opinion is that it is advantageous to develop inhalers containing several classes of long-acting bronchodilator drugs in an attempt to simplify treatment regimes as much as possible and to serve as a basis for improved 'triple therapy' combinations through co-formulation with novel anti-inflammatory compounds, such as inhaled PDE4 inhibitors, that could deliver three complementary therapeutic effects. © 2006 Elsevier Ltd. All rights reserved.
Cazzola, M., Matera, M.g. (2006). The effective treatment of COPD: Anticholinergics and what else?. DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, 3(3), 277-286 [10.1016/j.ddstr.2006.09.009].
The effective treatment of COPD: Anticholinergics and what else?
CAZZOLA, MARIO;
2006-01-01
Abstract
Long-acting bronchodilator therapy should be considered when a COPD patient is symptomatic. For patients whose conditions are not sufficiently controlled by monotherapy, combining medications of different classes seems a convenient treatment for obtaining better results. The current opinion is that it is advantageous to develop inhalers containing several classes of long-acting bronchodilator drugs in an attempt to simplify treatment regimes as much as possible and to serve as a basis for improved 'triple therapy' combinations through co-formulation with novel anti-inflammatory compounds, such as inhaled PDE4 inhibitors, that could deliver three complementary therapeutic effects. © 2006 Elsevier Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
